Research Article

SIMULTANEOUS ESTIMATION OF SACUBITRIL AND VALSARTAN IN BULK AND PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC

Kirtimaya Mishra¹*, K. Aditya Prasanna², Snigdha Rani Behera²

Affiliation and address of the authors

^{1*} Department of Pharmacy, Annamalai University, Chidambaram, Tamilnadu.

²Department of Pharmaceutical Analysis, Jeypore College of Pharmacy, Jeypore, Odisha.

ARTICLE INFO	ABSTRACT				
Article history:	A new and simpler method was developed with the Inert				
Received 29 May 2020	ODS 3V C18 column, linked to a C_{18} guard cartridge and				
Revised 09 June 2020	PDA detection at 239 nm, to quantitably detect Sacubitril				
Accepted 15 June 2020	(SAC) and Valsartan (VAL). The optimized mobile phase acetonitrile (ACN), triethylamine buffer (TEA) was pumped at 0.7 mL/min. The method was linear between 5-				
Keywords: Sacubitril, Valsartan, Simultaneous estimation, RP-HPLC.	pumped at 0.7 mE/mm. The method was mean between 3- 15 μ g/mL for SAC and 2.5-7.5 μ g/mL for VAL, statistically validated for its accuracy, precision, and linearity. The additives in the commercial tablet were found to have no interference in the method. The currently developed method for estimating compounds SAC and VAL associated with the tablet dosage form can be used routinely.				

©2020 Published by HOMES on behalf of RJPLS This is an open access article under the CC-BY-NC-ND License.

* Corresponding author:

Kirtimaya Mishra

^{1*}Kirtimaya Mishra M.Pharm., (Ph.D.,)

Research Scholar

Department of Pharmacy

Annamalai University, Chidambaram, Tamilnadu. 608002

Mail id:-kirtimishra.pharma@gmail.com

Mob No:- 9944937088

INTRODUCTION

Sacubitril (SAC) (**Fig.1**), chemically 3- $\{[(2S,4R)-1-\{[1,1'-biphenyl]-4-yl\}-5-ethoxy-4-methyl-5-oxopentan-2-$

yl]carbamoyl}propanoic acid. SAC is a white powder. The solubility of drug substance is Sparingly soluble in methanol,ethanol & acetonitrile. SACis a prodrug neprilysin inhibitor and is used in combination with VALis used to reduce cardiovascular event risk in chronic heart failure patients.





Fig 1: Structure of SAC

Valsartan (VAL), chemically (2S)-3methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5yl)phenyl]phenyl}methyl)pentanamido]buta noic acid as shown in Fig 2.



VAL is a White crystalline powder. VAL is freely soluble in alcohol,ether & chloroform. Literature review shows that some analytical procedures have been taken into account for estimation of SAC and VAL individually as stability indicating and in biological fluids or in combination with different drugs in pharmaceutical dosage forms.

For the simultaneous identification of SAC and VAL, both pharmaceutical dosage and biological fluids, all monotonous or expensive techniques, have been considered since the late HPLC [1-2] and UV spectroscopy [3].

MATERIALS AND METHODS

Chromatographic measurements were made on an RP-HPLC Shimadzu (LC 20 AT VP) model which consisted of an LC-20AD solvent delivery module, SPD-M20A prominence diode array detector, a rheodyne injector (model 7125, USA) valve fitted with a 20µl loop. The machine was operated using a SCL-10A system controller and a personal computer with chromatographically mounted Shimadzu software (LC Solution, Published 1-11SP1). Branson Sonicator was used to degass the mobile process (Branson Ultrasonic Corporation, USA). A 1 cm long quartz cell for spectrum recording was used with a UV double-beam spectrophotometric system (Systronices 2202 Mode UV-1601PC).

Chemicals and reagents

Working standards of SAC and VAL were purchased from Biotech Solutions, New Delhi. ACN, MeOH of HPLC grade and HCOOH was of analytical- reagent grade supplied by M/S SD Fine Chemicals, Mumbai, India. The HPLC grade water was prepared by using Milli-Q Academic, Millipore, and Bangalore, India. The pharmaceuticals entresto (Batch No: 659913A, MFG: APR 2018, EXP: APR 2021) were purchased from local medical shop.

Chromatographic condition

Chromatographic separations were carried out on an Inertsil ODS C₁₈column (250 mm× 4.6mmi.d., 5µm) connected with an Inertsil C₁₈ guard cartridge. The mobile phase consisted of TEA : ACN (pH 3.5 ±0.5) (50:50). A wavelength of 239 nm was selected for detection. The sample was injected at 20µl. The HPLC method was used in the laboratory setting (20±2 °c)

Preparation of Standard Solutions

In the mobile phase, SAC and VAL stock standard solutions were drawn up to prepare 1mg/ml solution. The ready to use stock arrangements were then shielded from light at $4^{\circ}C \pm 0.05$. During analysis day,the working standard solutions were freshly arranged by diluting the stock solutions with mobile phase.

Selection of detection wavelength

At 239 nm, SAC and VEL shown significant absorbance by PDA detector.

Preparation of Sample Solution

Ten tablets were weighed (each tablet entresto containing SAC-24mg and VAL-26mg and taken into a mortar and crushed to fine powder and uniformly mixed. In order to achieve weight equal to 10 mg SAC and 15 mg VAL, the tablet stocking solutions of SAC / VAL (μ g / ml) were produced and dissolved in a mobile phase enough. A 0.45micron syringe filter was then screened and sonicated for 5 minutes. The addition of 1.5 ml of stock solution to 10 ml of the mobile process is used in preparing the further dilutions in 5 replicates 100 μ g / mL of SAC, and in 150 μ g / ml of VAL.

Assay validation

The RP-HPLC method, optimized has been accepted for various parameters [4] in accordance with the guidelines [ICH] Q2 [R1].

Linearity and range

For linearity a concentration ranges from 5 to 15 μ g/mL ofSAC and 2.5 to 7.5 μ g/mL of VAL was prepared. By taking the peak area versus the concentration, a calibration graph was drawn. A study was conducted for correlation coefficient, intercept, slope and linear regression [5].

Sensitivity

The limit of detection (LOD) and limit of quantitation (LOQ) were determined respectively with formulas 3.3 s / S and 10 s / S, where s is the standard deviation from response (y-intercept) and S the slope of linearity plot was calculated[6].

Specificity

The specificity was determined by comparing sample solution analysis with findings from standard pharmaceuticals. [7].

Precision studies

Precision was calculated by taking 10 μ g/mL concentration of SAC and 6.25 μ g/mL of VAL sample ware analyzed six times on a similar day to find out any differences in the results [8].

Accuracy studies

Accuracy is the closeness in accordance between the accepted true value and the actual results obtained. Accuracy studies are typically measured by measuring the regeneration of a spiked analyte sample in the sample mixture to be tested. For accuracy studies, three different concentration of solution such as 50%, 100% and 150% were used. After injecting each concentration mean % recovery was calculated [9].

RESULTS AND DISCUSSION

Chromatographic development

Chromatographic analysis was developed using an Inertsil ODS C_{18} column (100mm× 4.6 mmi.d., 5µm). The mobile phase consists of TEA : ACN (pH 3.5 ±0.5) (50:50) and that was supplied at a flow rate of 0.7 mL/min. A wavelength of 239 nm was selected for detection. Fig. 3 shows the optimized chromatogram of SAC and VAL.




Fig. 3: Optimized chromatogram of SAC and VAL

Validation of the method


Linearity

The response from the analytes in the 5-15 μ g / mL of SAC and 2.5-7.5 μ g/mL of VAL

range was linear ($r^2=0.999$). The results wereshown in Table 1. Fig. 4 and Fig. 5 shows the calibration curve.

Table 1: Linear regression analysis of SAC and VAL

Parameters	SAC	VAL	
Linearity range (µg/mL)	5–15 µg/mL	2.5 to 7.5 µg/mL	
Correlation Coefficient (r ²)	0.999	0.999	
Slope	205.4	30.36	
Intercept	5.604	22.47	






Fig. 5: Linearity graph of VAL

The selected concentration gives acceptable accuracy and precision over a wide concentration range. The resultsdemonstrate that an excellent correlation coefficient between the absorbance and concentration of SAC and VAL.

Sensitivity

The LOD was found to be 0.015 μ g and 0.038 μ g for SAC and VAL respectively. The LOQ for SAC and VAL were found to be 0.004 μ g and 0.011 μ g respectively representing good sensitivity of the method.

Specificity

The standard and sample solutions obtained chromatograms do not conflict withwhich indicates method is highly selective.

Precision

In the estimation of SAC and VAL calculations (Table 2) have shown that the RSD level during the study has been < 2%.

These low RSD values show that the precision is good.

Table 2: Precision studies of SAC andVAL

Drug	Actual	Precision	%
	Concentration	Data	RSD
SAC	10 µg	99.99	0.0333
VAL	6.25 μg	99.99	0.0254

Accuracy

The accuracy study reveals influences on quantitative parameters of additives that are typically present in dosage forms. The recovery study data provided in Table 3 shows that more than 99% of the accurativity of quantifying SAC and VAL products is reliable to estimate commercialized formulation used in the study indicates that the proposed simultaneous HPLC-RP method is reliable.

Amour	nt taken	Amoun	it added	% rec	covery	%F	RSD
(µg/mL)		(μg/mL)					
SAC	VAL	SAC	VAL	SAC	VAL	SAC	VAL
10	5	5	2.5	96.33	100.56	0.003	0.005
10	5	10	5	101.67	100.87	0.007	0.003
10	5	15	7.5	100.65	100.31	0.005	0.004

Table 3: Results of recovery studies of SAC and VAL

ANALYSIS OF A MARKETED PREPARATION

The results obtained for the amount of SAC and VAL in tabletpowder against the label

claims werein good agreement it indicates that there is no interference from the excipients presents in the tablet. The percent assay was found to be 101.67% and 100.87%, for SAC and VAL respectively.

CONCLUSIONS

The plan to conduct this research work is to create and approve amethod utilizing a simple, rapid, sensitive, precise. and accurateRP-HPLC for the routine determination of SAC and VAL inbulkand pharmaceutical preparations. The proposed method is appropriate for pharmaceutical investigation indifferent analytical laboratories. The retention time and run timewere short, hence, requires less mobile phase for this technique, making it more economical and rapid. Consequently thetechnique can be utilized for the analysis of a large number of samples.

ACKNOWLEDGMENT

Our thanks to Department of Pharmacy, Annamalai University for the laboratory facilities provided to an outcome of this investigation.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

 Begum F, Rizwan S.H. Stability indicating analytical method development and validation for estimation of sacubitril and valsartan in bulk and pharmaceutical dosage form using RP-HPLC. Int J of Farmacia 2016; 2:79-87.

- Kokil S. U, Bhatia M. S. Simultaneous estimation of nebivolol hydrochloride and using RP HPLC. Ind J Pharm Sci.2009;71: 111–4.
- Tohidi M, Ramezani M, Mehramizi M. Application of continuous wavelet transform coupled with zero-crossing technique for the simultaneous spectrophotometric determination of sacubitril and valsartan in tablet dosage form. J Chem Health Risks 2019; 9:331-44.
- Monks K, Molnár I, Rieger H J, Bogáti B, Szabó E. Quality by Design: Multidimensional exploration of the design space in high performance liquid chromatography method development for better robustness before validation. J Chromatogr A 2012; 1232: 218-30.
- Rozet E, Ziemons E, Marini R D, Boulanger B, Hubert P. Quality by design compliant analytical method validation. Anal Chem 2012; 84: 106-12.
- Mishra K, Behera S, Mishra SR, Somesu M, Kiran Kumar B. A Validated stability indicating RP-HPLC method development for platelet aggregation inhibitor ticagrelor in bulk

and tablet formulation. J Glob Pharma Tech 2019; 11:12-18.

- Mishra K, Saragi B, Kiran Kumar B. Simultaneous estimation of sertraline and alprazolam in its bulk and tablet dosage form by RP-HPLC method. Asian P J Pharm Phyto. 2016; 1: 25-32.
- Mishra K, Kiran Kumar B, Muthu Kumari K, Subrahmanyam V. New analytical method development and validation of chlorpheniramine maleate by using uv-visible spectrophotometry. Indo Am J Pharm Sc 2016; 3: 767-72.
- Balamurugan K, Mishra K, Suresh R. Simultaneous estimation of linagliptin and metformin hcl in human plasma by RP-HPLC method. Int Res J Pharm 2019; 10:1-4.